Nufarm Limited (NUF) Earnings Call Transcript
May 21, 2025
Earnings Call Speaker Segments
We appreciate everyone being on the line, and thanks for joining Nufarm Limited's 1H25 Results Call. Everyone is currently in a listen-only mode. <<operator_script>> At this point, I'd like to pass the conference to Mr. Greg Hunt, CEO. Please go ahead.
Thanks, and good morning, everyone. Welcome to Nufarm's first half '25 results presentation. With me today are Brendan Ryan, Nufarm's CFO; Rico Christensen, Group Executive, Crop Protection Technologies, and Brent Zacharias, Group Executive, Seed Technologies. Let me pause briefly and point you to the disclaimer on Slide 2, and especially the statement concerning forward-looking statements. Before I turn to our first half result, I want to update you on the review of Seed Technologies that we announced today. As we've been discussing with you for some time, there are significant opportunities within Seed Technologies to create value across multiple seeds and traits platforms. Our hybrid canola, sorghum, and sunflower seeds platforms hold strong market positions and have a track record of above-market growth. They deliver more than $200 million in revenue annually, with high margins and strong cash generation. We hold the leading Canola position in Australia and are currently expanding in South America, where we see strong growth potential. We have invested heavily in commercializing our portfolio of the world first plant-based omega-3, and we've learned a lot about this technology over the past several years. The omega-3 platform is supported by favorable macro and industry trends, and with additional investment, we believe it has a bright future over the longer term.
Carinata sits at the heart of our bioenergy platform, and it's backed by a 10-year market development and commercial offtake agreement with BP that we signed in 2022. Demand for sustainable aviation fuel is climbing thanks to mandates brought in across multiple regions, and we believe there's an opportunity to scale this platform quickly. We also have a pipeline of new and emerging technologies, among them camelina in our omega-3 platform, energy cane in our bioenergy platform, and Biomass Oil Trait technology — an exciting development that could see use in bioenergy and FMCG markets. The value it could deliver is shown by the research agreement we announced recently with BP and Unilever. Over many years, we've put a significant amount of capital into growing seed technologies, building up our hybrid seeds platform, and guiding omega-3, carinata, and energy cane through the first stages of commercialization. These platforms and our new and emerging technologies carry significant value, but they need additional investment to reach their full potential. We think now is the right moment to look at alternative structures that would support and accelerate growth. We also think that bringing in outside equity will give current shareholders the chance to see the full value of these platforms realized sooner. Following an initial outreach to potential investors, we are starting a formal process to explore capital structure options for Seed Technologies.
We're going to look at approaches both for the whole business and platform by platform, with the aim of maximizing value. UBS has been brought in to help us with this review. Nothing is being ruled in or out at this point. There's no guarantee this process results in a transaction, and we'll update and report back to you on how it's progressing as appropriate. Moving now to the half, where we posted underlying EBIT of $103 million, earnings per share before material items of $7.02, and ended the period at leverage of 4.5 times. Profitability recovered strongly in Crop Protection, with underlying EBIT there rising 34% year-on-year. Our result took a negative hit from omega-3, which Brent will cover in more detail later in the presentation. Apart from omega-3, seeds put in a solid performance. We're speeding up the scale-up of biofuels. To that end, we plan a 3 times expansion in the carinata area planted in 2025 versus 2024. We're also building out our hybrid seeds, canola, sunflower, and sorghum position in South America. At the '24 results, we set out actions to improve return on funds, and I'm glad to say those actions are well advanced. We're taking steps to slow cost growth and holding to a target of $50 million in annualized run rate savings in overhead costs by the close of financial year '25.
By the close of the first half of '25, we've delivered a 22-day reduction in inventory versus a year earlier, and we remain firmly on course to cut inventory by 25 days year on year by the conclusion of '25. It's also encouraging to see that profitability in our Europe Crop Protection business is already showing a clear improvement. Beyond the initiatives covered when we announced the full-year '24 results, steps are now being taken aimed at lifting free cash flow. As things stand, we anticipate capital expenditure of roughly $200 million in financial year '26 — a substantial decrease compared with recent years. Seed Technologies is included within that amount. Brendan will address this subject later in the presentation, but I'd like to spend a few moments on leverage. We ended the period at 4.5 times. Leverage has risen since the full year, which mirrors a customary seasonal working capital build plus extra working capital tied to scaling our omega-3 platform. Some of you will spot — and quite reasonably note — that leverage has been climbing across the past several years. During that stretch, we have made substantial investments in our Crop Protection and Seed portfolios while also reinvesting in our manufacturing operations.
The investments we've made have brought better resilience and performance gains. At this stage, the investment needed to bolster our manufacturing resilience is largely behind us. We're recalibrating the omega-3 expansion so that the pace of commercialization is balanced against regulatory development and customer demand. For 2025, we intend to plant roughly half the omega-3 acres we planted in 2024, and elsewhere in the business we have further initiatives in motion to lift net working capital efficiency. Thanks to these steps, we can see a realistic route back to a lower leverage level. In line with our capital management principles, which concern leverage and free cash flow, no interim dividend will be paid. On first-half achievements: during the half we experienced a strong recovery in Crop Protection, helped by an improved cost of goods position. Volume grew across every region. EBIT improved strongly in APAC and Europe, notwithstanding some weather headwinds in Australia. Indeed, EBIT in Europe nearly doubled versus the prior year. Cash generation from North America was strong even though profit recovery was slower. We reached several significant milestones in our Crop Protection product pipeline. We announced an agreement with KingAgroot to develop a new proprietary non-selective herbicide for the Australian market.
This active ingredient, when used on its own as a knockdown herbicide, has delivered encouraging results, and it could become a highly valuable resource for Australian growers, since it brings several major difficult weeds under control. Hybrid canola in Australia turned in another strong result for us, even though drier conditions pushed sales down compared with the prior year. Over the half, we expanded our canola footprint in South America — a market that is growing, where we already hold a substantial share, and which now accounts for a meaningful portion of our worldwide canola volume. South America illustrates a market in which we can capture synergies spanning product range and genetics originating from Australia. In South America we finished a successful carinata program. We additionally secured further carinata certifications along with renewals, and these strengthen our GHG value credentials. Moving to the balance sheet, we delivered a substantial decrease in average net working capital to sales, which is now positioned inside our target range of 35% to 40%. This gain came primarily from reduced inventory in Crop Protection. We entered into new agreements with Unilever and BP, announced in late 2024, aimed at advancing development of Biomass Oil — a globally leading innovation backed by a substantial IP estate and research program focused on sustainable oil production for biofuels and FMC applications.
We've also kept moving forward nicely on growing the carinata program we run with BP. Down in Australia, we teamed up with Hort Innovation to develop and bring to market a precision application robotic sprayer built by Kilter, and that unit will see use in intensive, high-value crop markets. Now looking more closely at how our segments performed, APAC revenues came in slightly higher than the previous year, helped by favorable seasonal conditions throughout Asia and solid adoption of new products in Indonesia, which offset the dry weather in Australia. EBIT rose 34%, as a steadier pricing picture for active ingredients supported margin normalization and a robust profit rebound in Australian Crop Protection. We obtained rights to develop a new broad spectrum non-selective herbicide, which we aim to launch in the Australian market before 2030. And as I mentioned, this represents a major and exciting chance to meet a very substantial need among farmers grappling with the escalating challenge of herbicide resistance. In North America, we posted EBIT that fell 10% versus the prior year. North America has normalized more slowly than other regions. Pricing pressures, a season that arrived late, and just-in-time buying all weighed on the result and on volumes. Cash generation came in strong, fueled by a year-on-year decrease in inventory.
We closed out the period with a better cost of goods position, and we think we're in good shape for year-on-year growth in the second half. We delivered a substantial year-on-year decrease in net working capital to sales, thanks to lower inventories. On tariffs, the environment has been volatile and highly uncertain. A lot of the products we bring in from China are exempt from the reciprocal tariffs. For those hit with higher tariffs during the six-week stretch before last week's announcement cutting the reciprocal tariff level to 10%, we made the call not to import tariffs, and that could have some effect on sales in the second half. In Europe, we posted EBIT of $43 million, nearly double the prior year. We saw a strong rebound in sales and profitability and gained from favorable cropping conditions throughout the region. We've enhanced manufacturing reliability at Wyke, though we faced continued margin pressure. We delivered a substantial year-on-year decrease in net working capital to sales, thanks to lower inventories. Moving to Seed Technologies, where we reported revenue of $249 million and underlying EBIT of $15.9 million, the drop in EBIT versus the prior year came from lower licensing revenues, weaker margins in omega-3, and drier conditions in Australia.
On hybrid seeds, canola, sorghum, and sunflower all delivered solid results, though recent dry conditions took a toll on Australian canola. Sorghum volumes rose compared with a year earlier, while sunflower came in broadly flat versus the prior year. Pricing in the fish oil market has dropped considerably over the past few months, and that has hit sales and profitability at Aquaterra, resulting in a negative $28 million write-down of omega-3 inventories for the half. Against that backdrop, as I mentioned earlier, we have scaled back the 2025 production program and are taking action to lower cost of goods. Turning to carinata, we wrapped up a successful crop year in South America, with production in Argentina and Brazil. Grain from the 2024 South American harvest is now being shipped to Europe, where our partners will handle crush and sales. We secured further carinata proof of sustainability certifications, which strengthen the GHG value of our carinata. The production program for the 2025 carinata crop is underway, and we anticipate a significant expansion in production hectares and zones throughout South America. Before I hand over to Brendan, I want to summarize our near-term priorities. We have clarity on the actions required to improve profitability, generate higher returns, and delever the balance sheet.
We're building a culture where continuous improvement is embedded, supported by clear targets and stronger governance, and that's what drives our improvement work. We're continuing to pick up the pace on actions aimed at better returns on funds and improved cash flow. On the actions to achieve $50 million in annualized run rate savings by the end of '25, we've made good progress. At the half, we delivered a 22-day year-on-year reduction in inventory days, and we remain on track to achieve a 25-day year-on-year reduction in inventory by the end of financial year '25. Now that major works at our manufacturing plants are complete, we're shifting to a lower capital expenditure envelope, which we expect to be around $200 million in financial year '26. So peak CapEx is behind us. We expect to update you on our review of Seed Technologies towards the end of calendar year '25. And I'll now hand you over to Brendan.
Thanks, Greg, and good morning, everyone. For the half, revenue rose 3% compared with the same period a year earlier. The underlying gross profit margin was up 50 basis points year-on-year, reflecting a solid recovery in Crop Protection supported by active ingredient prices that have stabilized. Omega-3 gross margin fell year-on-year. Underlying EBITDA came to $206 million, down 6% year-on-year, while underlying EBIT was $103 million, down 15% year-on-year. Please note that we are shifting to EBIT as the primary measure of our operating profit. Statutory net profit after tax stood at $30 million. The year-on-year drop in statutory net profit was mainly attributable to omega-3 and portfolio expenditures. We are happy with how we are progressing on lowering average net working capital to sales, an important gauge of how efficiently we use our balance sheet. Average net working capital to sales came in at 39.2%, helped by disciplined inventory reduction in Crop Protection. Gains in Crop Protection were partly offset by higher omega-3 oil and grain inventories. Net working capital in Seed Technologies finished the half roughly $75 million above the prior year. On the whole, the average net working capital result of 39.2% represents a substantial improvement over the prior year. Underlying earnings per share before material items were $7.02 per share.
Return on funds employed came in at 3.2%, versus 3.6% a year earlier. On the whole, compared with the prior year, a strong Crop Protection outcome across revenue, underlying EBITDA and net working capital was offset by lower omega-3 earnings and a build in net working capital. As of March '25, net debt stood at $1.362 billion, up 12% year on year. That rise in net debt reflected weaker profitability, our capital expenditure program, the effect of omega-3 on net working capital, and currency translation. Crucially, funding headroom at the balance date was $265 million, bearing in mind that March represents the peak drawdown on seasonal funding. Our asset-backed lending facility plays an important role in how we manage liquidity; it is secured against receivables and inventory and flexes up and down to accommodate movement in those balances. Net leverage was 4.5 times underlying EBITDA, against 3.6 times a year earlier. Leverage felt the effect of higher net debt and a lower rolling 12-month EBITDA. If omega-3 and currency translation impacts were excluded, the leverage ratio would be roughly 3.8 times, versus the reported 4.5 times. I mention this in the context of our response plan for deleveraging. We have a solid plan in place to bring down net debt and leverage.
With these charts, I want to show the steps we're taking on deleveraging. On the debt side, we're scaling back the omega-3 program so that commercialization pace stays in balance with regulatory development. We keep concentrating on building solid momentum in net working capital reduction, especially around inventory management. On CapEx, over the last three years we put substantial investment into our manufacturing plants and into the Seed Technologies growth platforms for omega-3 and bioenergy. At this point we've passed peak CapEx. For financial year '26, targeted capital expenditure is roughly $200 million. We'll still see a seasonal build in the half year, followed by a meaningful unwind in the second half. Turning to the EBITDA side of leverage, omega-3 shouldn't deliver the same negative hit it gave this result. Our cost savings program, at a $50 million run rate, should offset cost growth, and we expect organic earnings growth backed by our portfolio of new product introductions. These steps should strengthen free cash flow generation and bring net debt down. On the timing of net debt reduction, we expect financial year '25 net debt to land above financial year '24, mainly because of the omega-3 impacts in the current year.
Fiscal year '26 stands to gain substantially from the steps we've laid out above, which should bring us into the target leverage range of 1.5 to 2 times underlying EBITDA. On top of that, the review of Seed Technologies might serve as a catalyst for meaningful deleveraging. Crop Protection revenue rose 4%, driven by volume gains in every region and a favorable product mix shift, though softer pricing partly offset that, reflecting lower active ingredient prices versus the prior year. Seed Technologies revenue fell 2.7% year-on-year. That decline stemmed largely from drier conditions in Australia, which hurt canola revenue. Licensing revenue likewise came in lower year-on-year. Our charts covering operating cash flow and net working capital show how seasonal working capital is — it peaks in the first half and unwinds considerably in the second half of the financial year. Net working capital at the close of the first half sat $100 million under the prior year, driven by a strong improvement in Crop Protection, partly offset by extra inventory tied to the omega-3 expansion. Half-year net operating cash flow moved to an outflow of $459 million. The main driver of that cash outflow was a seasonal build in net working capital, something we see every half year.
For the second half of financial year '25, we expect cash inflow to align with how net working capital unwound in prior years. Regarding the net working capital components, I've already noted the meaningful gain we've made on inventory performance. On trade receivables, our results still show tight control over commercial terms amid a competitive trading environment, along with solid collections. Trade payables keep normalizing as the business returns to a more typical replenishment rhythm. Thanks to these working capital gains, average net working capital to sales improved substantially, reaching 39.2% versus 47.1% a year earlier. During the FY '24 briefing, we made a commitment to cut inventory by 25 days. By the close of the first half, we have brought inventory days down by 22, on a rolling 12-month basis. A disciplined focus on the key levers — demand forecast accuracy, supply planning, supply chain agility, and inventory turnover — should allow this momentum to continue. We expect to hit our goal of a 25-day reduction in inventory days by year-end. That figure excludes any carryover of omega-3 product we may decide to hold during the second half.
For the six-month period, capital expenditure came in at $148 million, versus $110 million in the prior period. That year-on-year rise mostly reflects the timing of spend. We expect capital expenditure for the full year to land around $240 million. The amount above the $230 million expectation we gave at the full year stems from strategic investment opportunities that came up with the Yield10 camelina acquisition and the KingAgroot herbicide agreement for the Australian market. Those investments sit within intangibles. We rationalized underlying capital spend. The benefit of that, though, is expected to be offset by currency translation from a weaker Australian dollar. Investment in property, plant, and equipment went toward plant reliability and safety-critical programs, with substantial reinvestment into phenoxy manufacturing at Wyke. Some residual investment is still required in the second half, but as Greg said earlier in the presentation, we expect the rate of that investment to come down in the future. I'd now like to hand you over to Brent Zacharias, who will provide an update on the omega-3 canola platform.
Good morning, everyone. The omega-3 business has been through a very difficult stretch. I want to walk you through how we got here, where we stand now, and why we still have confidence in what this platform can deliver going forward. A number of years back, we chose to start expanding our omega-3 program before deregulation arrived in key markets. When we kicked off our 2024 production campaign roughly 18 months ago, fish oil markets were trading at record levels—near $7,800 per metric ton for Peru 24% omega-3 oil and $5,300 per metric ton for North Atlantic 18% omega-3 fish oil. Back then, the industry consensus was that prices would correct downward by roughly 25% to 30% and that supply would stay very tight even if Peru's quotas recovered. Lately, Peru—the biggest fish oil supply region—has announced two quotas that together amount to the largest granted since 2012. That has brought a substantial rise in supply, with prices for certified sustainable oils dropping about 70% from peak. You can see the supply increase in the leftmost chart on this page. In 2024, we saw the second-largest Peruvian anchovy quota of the past 10 years. Then, in April 2025, came the second-largest first quota over that same period.
Those quota hikes have clearly moved pricing. You can see that effect in the second chart from the left. A number of reference prices exist that one could use. We've attempted to keep it simple by concentrating on 2 reference prices. The North Atlantic price serves as a benchmark for sustainably sourced fish oils. During April, that North Atlantic reference price sat 15% under the five-year average. Additional benchmarks exist in the market too, and the chart displays a Chile blended import price. Last month, the average price reported for fish oil imports into Chile came to roughly $2,300 per metric ton. That figure was 15% under the North Atlantic price. Although Aquaterra is a sustainable oil, in atypical periods when supply outstrips demand as it does today, we must trade at competitive spot market levels into Chile. That is what produced the $28 million inventory value adjustment we have flagged in our accounts at the half year. At present we are evaluating market options for shifting inventory through the rest of the year. Looking at the long term, we remain confident about omega-3 demand. Our confidence rests on the fact that, over the long term, fish oil supply stays constrained notwithstanding the temporary effect of above-average Peru quotas.
Our focus right now is on getting Aquaterra accepted — that's a GM product — and it helps us enter the higher-value European market. Demand for omega-3 keeps growing, and we expect aquaculture production, rising incomes, urbanization, and dietary trends to keep driving that. Let me now walk you through where things stand with our omega-3 program. Given the current market environment, it's clear we need to refocus on making sure we have not just stable production but also cost efficiency, so the main objectives for the coming few years are to optimize our production zones and bring down cost of goods, which will secure long-term profitability for our oil products across pricing cycles. To get there, we're concentrating on three key areas: first, enhancing our technology from an agronomic performance standpoint; second, steadily lowering logistics and stewardship costs; and third, working to optimize production zones and supply routes. On agronomic performance, we confirmed substantial grain and oil yield gains with new-generation hybrid genetics, and that let us cut grower premiums by 37% in our 2025 contracts, which brings down cost of goods for oil sales in 2026. Second, our truck, rail, and storage logistics costs have been comparatively high, given where our production zones are, the distance to crush, and our commitment to keeping a separate grain supply chain from standard canola for stewardship purposes.
When we optimize those direct-to-crush production zones, our logistics expenses are already 9% lower overall across our 2025 footprints, and we expect a more significant decline as we shift further in 2026 and 2027. And third, and most important, as we've said before, once our regulatory approvals are fully complete, we'll be able to move larger proportional volumes into countries with substantially lower-cost production and logistics positions, such as South America and Australia. Deregulation should drive a step change reduction in cost of goods, and we're working to secure regulatory approvals in the appropriate markets. We've run pre-commercial production trials in Australia, and the results support a lower cost of goods position. We've also applied for permission to conduct stewarded trials in Argentina and are assessing other South American countries. We've completed trials in Chile as well, under cooperation with a government program, which also demonstrated strong performance. Our experience with hybrid canola genetics across the Southern Hemisphere suggests we should expect strong performance. The potential to produce within Latin America for the Chile market is expected to drive substantial advantage in cost efficiency. Together, these three initiatives give us a pathway to sustained profitability and our continued pursuit to be the most scalable and cost-efficient omega-3 alternative to fish oil.
Across the past few years, we've gained considerable understanding of our technology and built up a substantial revenue stream and customer base. To sum up, even though the market is difficult right now, the underlying fundamentals and the demand for this technology are still robust. We're also accelerating clear, meaningful actions to improve costs. In the coming years, as we gradually secure those production cost positions, the following stage of commercialization will concentrate on fulfilling dedicated customer agreements, balancing best-cost production zones with targeted volume delivery. Thank you. I'll now turn things back to Greg.
Thanks, Brent. I have a few closing remarks to make before we open things up for questions. Crop Protection got off to a strong start this year, and we believe our position is a good one. That said, a number of uncertainties might affect the second half. Should fish oil pricing remain as weak as it is right now, we would anticipate EBITDA from Seed Technologies coming in roughly $20 million under the prior year for the second half. Because fish oil prices have come in lower than we anticipated, we no longer expect to reach $100 million of revenue from omega-3 in financial year '25. At present we are reviewing the options available to us for managing omega-3 inventory, and that review will affect where revenue and inventory end up for the full year. Crop Protection showed a good improvement in half one, but a range of uncertainties makes projecting the second half difficult for us. The U.S. tariff situation remains fluid and is generating uncertainty around supply, demand, and pricing outcomes. We believe our supply chains and our manufacturing operations at Wyke and Laverton leave us well-positioned. Even so, how the broader industry might behave introduces a degree of uncertainty. We do expect some benefit from products manufactured in the U.K. and Australia, but that benefit will probably be fairly small, since volumes imported ahead of tariffs taking effect have increased.
The anti-dumping duties on 2,4D products from China and India, which stay in place for five years, should give our Australian-made product a bit of breathing room. In Europe, we saw a strong recovery during the first half, helped by favorable seasonal conditions and the steps we took to start rightsizing the cost base. We don't anticipate the same pace of improvement in the second half. Australia had a more stable cost of goods position in the first half, and we expect that to carry on, with the caveat around possible tariff impacts that I mentioned earlier. That said, if the current dry conditions in Australia persist, that would hurt the second half. Management is still focused on cutting costs and lifting return on capital. We're on track for a 25-day year-on-year inventory reduction, excluding the omega-3 impact, and on track to deliver $50 million in run rate annualized cost savings by the end of financial year '25. On other financial items for the full year, we now expect capital expenditure of roughly $240 million. The increase since the full year outlook comes from our decisions regarding Yield10 and the Australian herbicide agreement with KingAgroot.
Apart from those items, we'd anticipate landing at roughly $230 million on a constant currency basis. For D&A, we're looking at about $220 million, and net interest expense should be near $95 million, which includes the cost of FX hedging. Even with the omega-3 setback this year, we've posted a solid first-half result and feel confident about the future. Grain prices have come up from recent lows. The stocks-to-use ratio for major grains is still tight. Planting conditions across major markets are broadly positive, and demand for seed and crop protection products continues to be strong. Active ingredient prices have largely stabilized, and channel inventories sit at low levels. Our pipeline of differentiated products is strong, with several key products expected to launch by 2028. We hold a leading position in Australia with our canola varieties, and hybrid seeds in South America keep growing. We see a pathway to long-term profitability in our omega-3 canola platform. Fish oil prices are at five-year lows. We'll manage production in line with industry conditions and keep advancing regulatory approvals and cost of goods reduction. We anticipate strong growth in bioenergy. The adoption of SAP mandates in the European and other markets gives us confidence in biofuel demand, with carinata plantings rising in '25 for '26 oil and sales.
Brent Zacharias and Rico are going to join Brendan and me for the Q&A, and at this point I'll turn things back over to the operator.
Our next question is from John Purtell of Macquarie. The line is yours.
Morning, Greg and Brendan. I have a couple of questions, if I may. On the Seeds Tech review, I suppose the question of why now — I appreciate the seeds business has different parts — but I suppose, why now, when fish oil prices are depressed, and understanding that there are short-term versus longer-term perspectives, though you're clearly at a depressed earnings level, certainly for the omega-3 business.
Yes. Thank you for that question, John. I suppose back when Seed Technologies was a smaller operation, we felt it was logical for it to remain part of Nufarm and to be financed through the cash flows coming out of our Crop Protection business. But as it now advances to the next phase of growth, it genuinely needs more funding than Nufarm on its own is able to supply. So in our view the optimal answer is to bring in external capital to back that next stage of growth. Over the recent period, we've had some inbound interest, and given the capital required to keep growing and to support that growth, we believe the moment is right to look into those opportunities. On omega-3 in particular, as Brent mentioned, it has been affected by a temporary oversupply situation, yet we see longer-term demand for omega-3 as favorable, and wild fish are unable to provide it consistently. So we believe that, at scale, our technology can offer a sustainable and competitive source of supply. And I suppose our view is that sophisticated investors will see past the temporary situation and, hopefully, recognize what we believe to be long-term value in that platform.
Thanks, Greg. And a quick second question about the Australian business. Clearly, you mentioned some dry conditions there. Could you speak to what the outlook looks like for the second half? I appreciate that's still kind of unfolding, but also any sort of — I suppose there are seasonal effects and maybe anything sort of structural there from increased China imports, if indeed they look to find other homes outside of the U.S.
Okay, so as we mentioned, margins have improved thanks to lower COGS. Trading has been affected by the dry conditions starting in March, so that covers April and May. For the rest of Asia — Indonesia and the rest of Asia — things look pretty much in line with last year, and we do have some flexibility when it comes to our 2,4D products. What I mean is, we'll prioritize supplying the domestic market, but we're also going to have additional production. We'll be looking to direct that into the North American market so we can maximize returns. So I suppose it's hard to make a call at this point. I think we believe, based on our current forecast, that Australia can probably — sorry, APAC will deliver a result in the second half similar to what we saw last year.
I appreciate that.
Thanks. We’ll take the next question from Owen Birrell at RBC. Go ahead, please.
Yes. Thank you. Perhaps I could shift focus to North America, where the market appears to be somewhat challenged, at the — I suppose, at the bottom. We were, I guess, sensing a few green shoots where demand was concerned earlier in the year. And although we hadn't observed it in price, I believe people expected pricing to begin bouncing back. I'm just curious whether that remains true and whether this, I guess, weak market climate right now is merely short-term uncertainty, or whether something somewhat more structural is taking place there?
Thanks. Thanks, Owen. Appreciate the question. Look, no, structural isn't how I'd characterize it. The market over there keeps running on a just-in-time basis, in my view. Tariff-related uncertainty has definitely made people more cautious when it comes to channel purchasing, though with channel inventories sitting at low levels, we'd anticipate a second half driven by better volumes. So I'd say that, unlike Australia — where we'd expect much the same in the second half — we're well positioned in North America for a stronger second half on the back of increased volumes.
Does that remark stem from your earlier point about a later start to the season in North America? Obviously, a delay means things get going afterward and therefore carry into the second half. Is that what gives you confidence in that view?
Right, that's right. The season is likely running about two or three weeks behind schedule. So the sales we'd typically have recorded in the first half — what I mean is, we'll recover some of them in the second half.
Could I also ask about how competition is shaping up over there? Because clearly, when we look at pricing on that volume, there are obviously quite a few rivals out there pursuing it. Do we expect that demand to push prices higher, or should pricing really keep staying underwhelming through the second half?
Yeah. No, see, I think that’s — you’ve got it right. It’s an extremely competitive setting. So volume going up is what I’d anticipate, though I don’t anticipate any meaningful margin gain in the second half.
That's great. I appreciate it.
Thanks. Our following question is from Jonathan Snape at Bell Potter. Go right ahead.
Yeah, guys. So, look — there are a couple of questions. I may split them into two batches, since the first is fairly simple. I just noticed that this time around I wasn't able to locate the payables financing utilization for the first half. Could you share that figure — what was sitting in those off-balance sheet facilities?
Thanks, Jonathan. Yes. On supplier finances, that balance stood at roughly $125 million, and that's fairly consistent with where it sat at the full year last year.
Thanks. Now, regarding the second item, it relates to the seeds part of the equation. I noticed the other week — I believe UPL sold an additional 12.5% stake in its Advanta business, which on a look-through basis implied a valuation of nearly $2.8 billion, if my math is right. And that was for a business that, I think, was generating roughly $140 million in EBITDA, which doesn't seem too far off from the multiple at which they sold that stake to KKR a couple of years ago — it's approaching 20 times. Now that you've begun this process, are you considering — or has the inbound interest been at multiples similar to what we can observe elsewhere? Because I know that as you carry it on the books at around $950 million, you haven't impaired it at all, but it just appears that some large transactions are taking place, and I'm simply trying to determine whether that might be what has prompted this, or whether it's the performance.
Well, it's definitely not about performance, as I mentioned before. I believe we have something unique and scalable — or at scale right now. I just don't think we'll be commenting specifically on what valuation expectations look like. As I've said, I think we have very valuable platforms, a strong earnings base coming from our hybrid seeds business, and future growth potential in bioenergy and omega-3. And I suppose the process will let us assess the value of various growth opportunities, whether that's the whole business, or hybrid seeds canola, or a bioenergy platform. I'd say we've made significant investments in building these platforms over — I guess over the last five years, we've put nearly $300 million into CapEx, which makes up roughly nearly 30% of the CapEx that investment — that new farms invested during that period.
Let me try putting that another way. That $950 million figure — have I got the arithmetic right regarding how it's being carried at present, which I take to be the net assets of the Seed Technologies platform? And once you began this process, I'd imagine you ran something like a valuation test against that to determine whether an impairment was warranted. Would that be a fair characterization or not?
Yes, Jonathan. I’ll comment on that. Regarding the earnings impact that omega-3 delivered this year, that prompted a review of the asset’s carrying value. We carried out the appropriate testing and review of carrying value against recoverable amount, and at that point there was headroom, so no impairment or adjustment to that value was needed.
Yeah, that $950 million book value — does it cover the whole platform? I'm looking through the segment notes you gave, or is some of it tucked away in corporate? I just can't find it.
Yes, regarding my estimate — let's reconnect so I can verify it with you. I don't believe it reaches as much as $950 million. Mine sits closer to somewhere between $750 million and $800 million, though we can check that and get back to you.
That's great. Thanks a lot.
Thanks. We’ll take the next question from Evan Karatzas at UBS. Go ahead, please.
Morning, everyone. Sorry if this has come up already — I’m bouncing between a few calls. On the $75 million Crop Protection pricing headwind, at today’s prices I imagine you’ve got some visibility there, but could you say when that ceases to be a headwind for the group, please?
Yes. That figure is $75.5 million. I suppose, going back to what Greg said earlier, it's really quite difficult to predict and estimate when the recovery to long-term averages will happen, I guess. Regarding, I suppose, stimulus in the market around demand, we are seeing the growth and inventory positions destocking, but I guess what's unknown is when we see that sort of price come back up. So I guess in relation to the North American comment, we continue to see probably gross margin holding. That's in terms of a rate percentage. Revenue will be influenced more by volume as opposed to pricing.
Yes. Okay, understood. That’s clear. And then regarding tariffs and the effect there, I realize it’s clearly changing all the time. Could you perhaps give us a little, just somewhat more detail? Just how should we think about the tariff impact in North America on Nufarm? Maybe if possible, any kind of range in dollar millions, and how you’re viewing the effect on farmer demand as well as whether it results in higher prices too?
Yes. Well, thanks, Evan. The thing I'd highlight is what I mentioned during the prepared remarks: many of the goods we bring in from China actually fall outside the tariffs. So the tariff right now is 10%, though every one of those products carries a 20% fentanyl tariff. And the thinking is that those extra costs will just get passed along to customers. There's a 90-day pause on reciprocal tariffs, so I don't anticipate a meaningful effect in the second half. The one item I flagged before was the six-week stretch when tariffs stood at 125% — during that window we chose not to import products. That could weigh on sales in the second half, since we simply lack the tariffs — sorry, we lack the stock. The third bucket involves the 2,4D anti-dumping and countervailing duties. Those came in, if I recall correctly, around May, and sit at roughly 150%. That gives — and this applies to 2,4D — that gives us some flexibility, once domestic demand is met, to move our Australian 2,4D volumes into the North American market, though I'd view that as more of an effect in '26, mainly because I believe there was some front-running of volumes into the U.S.
Because we expect those dumping duties to come in as they did back in, I believe, May. So it's more of a — since they stay in effect for 5 years, the bigger effect lands in '26 and afterward.
Yeah, okay, sounds good. Thanks, everyone. I appreciate it.
Andrew Scott of Morgan Stanley is next in the queue with a question — you have the floor.
Thank you, and good morning. Greg, I'd like to zero in on the balance sheet for a moment. You mentioned 4.5 times net debt to EBITDA in your answer to Snapey's question, and there are off-balance sheet items. There are also step-up prefs, which, I realize, don't fall under a covenant guise, but they are relatively expensive financing. How can you make us comfortable that this balance sheet is appropriate?
Thanks, Andrew. On the leverage point, as I mentioned before, the key items are, first, our funding structure is covenant-light. We've moved past the peak borrowing requirement as of the balance date. So liquidity isn't a concern for us. The debt increase stems from omega-3 and some currency translation, and there's also a timing element related to CapEx spending, which, on a full-year basis, comes back to roughly $240 million. So I laid out the steps we're taking to deleverage, which involve the CapEx reduction; it involves scaling back the redundant omega-3 so it won't have the same effect on working capital and earnings. There's also the cost savings side of getting that run rate up to $50 million by year-end. And then likely we'll also see some earnings benefit from the new product introductions they have, which continue to help on the earnings side. So the benefits of all those actions, I guess, will mostly flow into FY '26 in terms of bringing us back to that leverage range of 1.5 to 2 times underlying EBITDA.
All right, thanks. And then just secondly — right now the stock is down 25%. There seems to be a meaningful miss versus the Street at EBIT and EBITDA. I'm just wondering why this is the first time we're hearing about it. Is it that you actually feel the full year numbers are broadly consistent and we're just getting the skew wrong, or why are we only hearing about this today?
Yes. On the disclosure side—look, that's always front and center for us, and we give it careful thought every single day. I suppose the benchmarks people use for expectations differ, I guess, from one part of the market to another. Our expectation for EBITDA in that respect came in at $230 million. So for underlying EBITDA in the half, it was roughly around 10%. And I guess as far as the overall full-year result goes, there are plenty of uncertainties—particularly, I guess, two main ones: fish oil pricing, meaning where it stands today and where it might go from an outlook standpoint. And then especially, I guess, tariffs, which are also shifting in nature and in fact move day by day, week by week. So I guess those were the factors we took into account through this, and I guess that's when we reflected, I guess, our narrative regarding the outlook.
All right, thanks. That's where I'll stop.
Thank you. At this point, we have no more questions. I'll return the call to Mr. Hunt, who will offer some closing comments.
Well, I appreciate all of you taking the time today, and we're looking forward to connecting with some of you in the next few days. Thank you.
That brings today's conference to a close. We appreciate everyone joining us. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nufarm Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.